Solid Bio clears partial hold, but DMD gene therapy trial is still on hold – FierceBiotech
FierceBiotech |
Solid Bio clears partial hold, but DMD gene therapy trial is still on hold
FierceBiotech Solid Biosciences halted the phase 1/2 trial of its Duchenne muscular dystrophy treatment in March, after being hit with a pair of FDA clinical holds. The biotech has now fixed the manufacturing issue that led to a partial clinical hold on the study … Full FDA letter in hand, Solid Bio says it's working to reverse clinical hold on its DMD gene therapy Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy Solid Bio receives FDA Clinical Hold letter related to DMD candidate SCT-001, manufacturing questions addressed |
